Artículo
SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients
Bizzotto, Juan Antonio; Sanchis, Pablo Antonio
; Abbate, María Mercedes
; Lage Vickers, Sofia
; Lavignolle, Rosario; Toro, Ayelén; Olszevicki, Santiago; Sabater, Agustina; Cascardo, Florencia Laura
; Vazquez, Elba Susana
; Cotignola, Javier Hernan
; Gueron, Geraldine
Fecha de publicación:
10/2020
Editorial:
Elsevier
Revista:
iScience
ISSN:
2589-0042
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
In a published case-control study (GSE152075) from SARS-CoV-2-positive (n = 403) and -negative patients (n = 50), we analyzed the response to infection assessing gene expression of host cell receptors and antiviral proteins. The expression analysis associated with reported risk factors for COVID-19 was also assessed. SARS-CoV-2 cases had higher ACE2, but lower TMPRSS2, BSG/CD147, and CTSB expression compared with negative cases. COVID-19 patients´ age negatively affected ACE2 expression. MX1 and MX2 were higher in COVID-19 patients. A negative trend for MX1 and MX2 was observed as patients´ age increased. Principal-component analysis determined that ACE2, MX1, MX2, and BSG/CD147 expression was able to cluster non-COVID-19 and COVID-19 individuals. Multivariable regression showed that MX1 expression significantly increased for each unit of viral load increment. Altogether, these findings support differences in ACE2, MX1, MX2, and BSG/CD147 expression between COVID-19 and non-COVID-19 patients and point out to MX1 as a critical responder in SARS-CoV-2 infection.
Palabras clave:
COVID-19
,
SARS-CoV-2
,
MX1
,
TRANSCRIPTOMICS
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IQUIBICEN)
Articulos de INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CS. EXACTAS Y NATURALES
Articulos de INSTITUTO DE QUIMICA BIOLOGICA DE LA FACULTAD DE CS. EXACTAS Y NATURALES
Citación
Bizzotto, Juan Antonio; Sanchis, Pablo Antonio; Abbate, María Mercedes; Lage Vickers, Sofia; Lavignolle, Rosario; et al.; SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients; Elsevier; iScience; 23; 10; 10-2020; 1-21
Compartir
Altmétricas